Taxol administered as a 120 hour infusion
- 1 November 1992
- journal article
- Published by Springer Nature in Investigational New Drugs
- Vol. 10 (4) , 275-278
- https://doi.org/10.1007/bf00944181
Abstract
A Phase I trial of Taxol administered as a 120 h infusion once every 3 weeks was conducted in 20 patients with advanced cancer. The initial dose was 5 mg/m2/d (25 mg/m2 total dose) and patients received 10 mg/m2/d, 25 mg/m2/d, 30 mg/m2/d and 36 mg/m2/d. Forty-four courses of taxol were administered and all patients were evaluable for toxicity. Grade 4 leukopenia was the dose limiting toxicity observed in 50% of patients treated with 36 mg/m2/d. Significant mucositis was also observed at 30 and 36 mg/m2/d. All toxicity resolved within three weeks of treatment and no cumulative toxicity was observed. No neurotoxicity or cardiotoxicity was observed and no episodes of hypersensitivity reaction were noted. We conclude that 30 mg/m2/d is an appropriate dose for phase II testing of this schedule.Keywords
This publication has 7 references indexed in Scilit:
- Cardiac disturbances during the administration of taxol.Journal of Clinical Oncology, 1991
- Taxol: A Novel Investigational Antimicrotubule AgentJNCI Journal of the National Cancer Institute, 1990
- Hypersensitivity reactions from taxol.Journal of Clinical Oncology, 1990
- Taxol: an antimitotic agent with a new mechanism of actionPharmacology & Therapeutics, 1984
- Microtubule stabilization by taxol inhibits initiation of DNA synthesis by thrombin and by epidermal growth factorCell, 1981
- Taxol stabilizes microtubules in mouse fibroblast cells.Proceedings of the National Academy of Sciences, 1980
- Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifoliaJournal of the American Chemical Society, 1971